Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07502495 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
A Phase 2 study, sponsored by Biomea Fusion.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07502495 is a Phase 2 study that is actively recruiting participants, run by Biomea Fusion. The registered enrollment target is 60 participants.
The verdict
NCT07502495, a Phase 2 study, is actively recruiting participants, sponsored by Biomea Fusion.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes who are not achieving glycemic targets despite antihyperglycemic medications.
Interventions
- DRUG Placebo
- DRUG icovamenib 100mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-03-27 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07502495
The ClinicalTrials.gov registry entry for NCT07502495 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biomea Fusion, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07502495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07502495 about?
NCT07502495 is a clinical study titled "Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets". This is a Phase 2, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes who are not achieving glycemic targets despite antihyperglycemic medications.
What is the current status of trial NCT07502495?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-03-27. Estimated completion is 2027-07.
What interventions are being tested in trial NCT07502495?
The interventions under investigation include: Placebo (DRUG), icovamenib 100mg (DRUG).
Who is sponsoring clinical trial NCT07502495?
This trial is sponsored by Biomea Fusion, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.